JSPRClinical Trials•globenewswire•
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
Sentiment:Positive (90)
Summary
11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 14, 2025 by globenewswire